A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression

JAMA

Volumn 275, Issue 10, 1996, Pages 761-767

  Mason, Barbara J ^a   Kocsis, James H ^b   Ritvo, Eva C ^a   Cutler, Robert B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DESIPRAMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; XEROSTOMIA;

EID: 0030009226     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.10.761     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
2. Polich JM, Armor DJ, Braiker HB. Stability and change in drinking patterns. In: The Course of Alcoholism: Four Years After Treatment. New York, NY: John Wiley & Sons; 1981:159-200.
3. Gordis E. Relapse and craving: a commentary. Alcohol Alert. 1989;6:3.
4. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
5. O'Malley SS, Jaffe AJ, Change G, Schottenfeld RS, Meyer RE, Rounsaville BJ. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry. 1992;49:881-887.
6. Mason BJ, Ritvo EC, Morgan RO, et al. Adouble-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol Clin Exp Res. 1994;18: 1162-1167.
7. Helzer JE, Pryzbeck TR. The co-oceurrenee of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988;49:219-224.
8. Regier DA, Farmer ME, Rae DS, et al. Comorbiditv of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
9. Berkson J. Limitations of the application of four-fold tables to hospital data. Biol Bull. 1949;2:47-53.
10. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45:1023-1031.
11. Pottenger M, McKernan J, Patrie LE, Weissman MM, Ruben HA, Newberry P. The frequency and persistence of depressive symptoms in the alcohol abuser. J Nerv Ment Dis. 1978;166:562-570.
12. Hatsukami D, Pickens RW. Posttreatment depression in an alcohol and drug abuse population. Am J Psychiatry. 1982;139:1563-1566.
13. Berglund M. Suicide in alcoholism. Arch Gen Psychiatry. 1984;41:888-894.
14. Fulop G, Strain JJ, Vita J, Lyons JS, Hammer JS. Impact of psychiatric comorbidity on length of hospital stay for medical/surgical patients: a preliminary report. Am J Psychiatry. 1987;144:878-882.
15. Saravay SM, Steinberg MD, Weinschel B, Pollack S, Alovis N. Psychological comorbidity and length of stay in the general hospital. Am J Psychiatry. 1991;148:324-329.
16. Dvoredsky AE, Cooley HW. Comparative severity of illness in patients with combined medical and psychiatric diagnoses. Psychosomatics. 1986; 27:625-630.
17. Greenberg PE, Finkelstein SN, Berndt ER, The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-478.
18. Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993;150:963-965.
19. Feighner JP, Rubins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26:57-63.
20. Schuckit MA. Alcoholism and other psychiatric disorders. Hosp Community Psychiatry. 1983;34: 1022-1027.
21. Schuckit MA. The clinical implications of primary diagnostic groups among alcoholics. Arch Gen Psychiatry. 1985;42:1043-1049.
22. Schuckit MA. Genetic and clinical implications of alcoholism and affective disorder. Am J Psychiatry. 1986;143:140-147.
23. Ciraulo DA, Jaffe JH. Tricyclic antidepressants in the treatment of depression associated with alcoholism. J Clin Psychopharmacol. 1981;1:146-150.
24. Cornelius JR, Salloum IM, Cornelius MD, et al. Fluoxetine trial in suicidal depressed alcoholics. Psychopharmacol Bull. 1993;29:195-199.
25. Malka R, Loo H, Ganry H, Souche A, Marey C, Kamoun A. Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry. 1992;15:66-71.
26. Shaw GK, Majumdar SK, Waller S, MacGarvie J, Dunn G. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry. 1987;150:164-168.
27. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995; 152:391-397.
28. Mason BJ, Kocsis JH. Desipramine treatment of alcoholism. Psychopharm Bull. 1991;7:155-161.
29. Naranjo, CA, Sellers EM, Lawrin MO. Modulation of ethanol intake by serotonin inhibitors. J Clin Psychiatry. 1986;47(April suppl):16-22.
30. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanzhez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984;35:374-381.
31. Naranjo CA, Sellers EM, Sulivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitors citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987;41:266-274.
32. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther. 1989; 46:301-309.
33. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Eemus D, Sellers EM. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990;47:490-498.
34. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16:261-265.
35. Holder HD, Hallan JB. Impact of alcoholism treatment on total health care costs: a six-year study. Adv Alcohol Subst Abuse. 1986;6:1-5.
36. Zook CJ, Moore FD. High-cost users of medical care. N Engl J Med. 1980;302:996-1002.
37. Holder HD, Blose JO. Alcoholism treatment and total health care utilization and costs: a four-year longitudinal analysis of federal employees. JAMA. 1986;256:1456-1460.
38. Fuller MG. A new day: strategies for managing psychiatric and substance abuse benefits. Health Care Manage. 1994;19:20-24.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
40. Litten RZ, Allen JP. Pharmacotherapy for alcoholics with collateral depression or anxiety: an update of research findings. Exp Clin Psychopharmacol. 1995;3:87-93.
41. Sobell LC, Sobell MB, Ward E, eds. Evaluating Alcohol and Drug Abuse Treatment Effectiveness: Recent Advances. New York, NY: Pergamon Press; 1980:129-150.
42. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
43. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91:199-209.
44. Folstein MF. The Mini-Mental State Examination. In: Crook T, Ferris S, Bartus R, eds. Assessment in Geriatric Psychopharmacology. New Canaan, Conn: Mark Powley Assoc Inc; 1983:46-51.
45. Andreason N, Endicott J, Spitzer R, et al. The family history method using diagnostic criteria: reliability and validity. Arch Gen Psychiatry. 1977; 34:1229-1235.
46. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull. 1985;21:1069-1072.
47. Kissin B, Charnoff SM, Rosenblatt SM. Drug and placebo responses in chronic alcoholics. Psychiatr Res Rep. 1968;24:44-60.
48. Mindham RHS, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med. 1973;3:5-17.
49. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykell E. Treatment of depression by drugs and psychotherapy. Am J Psychiatry. 1974;131: 186-191.
50. Suckow RF, Cooper TB. Simultaneous determination of imipramine, desipramine, and their 2-hydroxy metabolites in plasma by ion-par reversed-phase high-performance liquid chromatography with amperometric detection. J Pharm Sci. 1981;70:257-261.
51. Nelson JC, Jatlow P, Quinlan DM, et al. Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry. 1982;39:1419-1422.
52. SPSS Inc. SPSS/PC+. Chicago, Ill: SPSS Inc. Marifa J. Norusis; 1990.
53. Puri ML, Sen PK. Nonparametric Methods in Multivariate Analysis. New York. NY: John Wiley & Sons; 1971.
54. Brown SA, Schuckit MA. Changes in depression among abstinent alcoholics. J Stud Alcohol. 1988;49:41-417.
55. Brown SA, Inaba RK, Gillin C, Schuckit MA, Stewart MA, Irwin MR. Alcoholism and affective disorder: clinical course of depressive symptoms. Am J Psychiatry. 1995;152:45-52.
56. McBride WJ, Murphy JM, Lumeng L, Li TK. Effects of Ro 15-4513, fluoxetine, and desipramine on the intake of ethanol, water and food by the alcohol-preferring (P) and non-preferring (NP) lines of rats. Pharm Biochemistry Behav. 1988;30:1045-1050.
57. Ciraulo DA, Alderson IM, Chapran DJ, et al. Imipramine disposition in alcoholics. J Clin Psychopharmacol. 1981;68:819-822.
58. Sandoz M, Vandel S, Vandel B, Bonin B, Allers G, Volmot R. Biotransformation of amitriptyline in alcoholic depressive patients. J Clin Pharmacol. 1981;24:615-621.
59. Mason BJ, Kreek MJ, Kocsis JH, Ritvo EC, Kerner RB. Desipramine metabolism in recovering alcoholics. Presented at the New Clinical Drug Evaluation Unit (NCDEU) annual meeting; May 27, 1992; Boca Raton, Fla.